Effects of San-Huang-Xie-Xin-Tang on U46619-induced increase in pulmonary arterial blood pressure

Journal of Ethnopharmacology

Volumn 117, Issue 3, 2008, Pages 457-462

  Tsai, Hsin Hung ^a   Chen, Ing Jun ^a,b   Lo, Yi Ching ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cardiovascular effects; COX 2; PDE5; ROCK II; San Huang Xie Xin Tang; U46619

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; CYCLOOXYGENASE 2; GUANYLATE CYCLASE; GUANYLYL CYCLASE ALPHA1; GUANYLYL CYCLASE BETA1; PHOSPHODIESTERASE V; PLANT EXTRACT; RHO KINASE; SAN HUANG XIE XIN TANG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; LUNG ALVEOLUS CELL; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; UPREGULATION; VASOCONSTRICTION; WESTERN BLOTTING;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; BLOTTING, WESTERN; CELL SEPARATION; CELL SURVIVAL; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; CYCLOOXYGENASE 2; DRUGS, CHINESE HERBAL; ISOMETRIC CONTRACTION; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; VASOCONSTRICTOR AGENTS;

RATTUS; SCUTELLARIA RADIX;

EID: 42749084559     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2008.02.024     Document Type: Article

References (44)

1. 2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation 88 (1993) 2117-2122
2. Black S.M., Sanchez L.S., Mata-Greenwood E., Bekker J.M., Steinhorn R.H., and Fineman J.R. sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. American Journal of Physiology. Lung Cellular and Molecular Physiology 281 (2001) L1051-L1057
3. Bova S., Padrini R., Goldman W.F., Berman D.M., and Cargnelli G. On the mechanism of vasodilating action of berberine: possible role of inositol lipid signaling system. Journal of Pharmacology and Experimental Therapeutics 261 (1992) 318-323
4. Carbone R., Bossone E., Bottino G., Monselise A., and Rubenfire M. Secondary pulmonary hypertension-diagnosis and management. European Review for Medical and Pharmacological Sciences 9 (2005) 331-342
5. Carvajal J.A., Germain A.M., Huidobro-Toro J.P., and Weiner C.P. Molecular mechanism of cGMP-mediated smooth muscle relaxation. Journal of Cellular Physiology 184 (2000) 409-420
6. Chen H.C., and Hsieh M.T. Hemodynamic effects of "san-huang-hsieh-hsin-tang" in patients with essential hypertension. American Journal of Chinese Medicine 14 (1986) 153-156
7. Chen H.C., and Hsieh M.T. Two-year experience with "San-Huang-Hsieh-Hsin-Tang" in essential hypertension. American Journal of Chinese Medicine 14 (1986) 51-58
8. Chen Z.Y., Su Y.L., Lau C.W., Law W.I., and Huang Y. Endothelium-dependent contraction and direct relaxation induced by baicalein in rat mesenteric artery. European Journal of Pharmacology 374 (1999) 41-47
9. Chiou W.F., Yen M.H., and Chen C.F. Mechanism of vasodilatory effect of berberine in rat mesenteric artery. European Journal of Pharmacology 204 (1991) 35-40
10. Dogne J.M., de Leval X., Hanson J., Frederich M., Lambermont B., Ghuysen A., Casini A., Masereel B., Ruan K.H., Pirotte B., and Kolh P. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Current Medicinal Chemistry 11 (2004) 1223-1241
11. Fagan K.A., Oka M., Bauer N.R., Gebb S.A., Ivy D.D., Morris K.G., and McMurtry I.F. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. American Journal of Physiology. Lung Cellular and Molecular Physiology 287 (2004) L656-L664
12. 2+-sensitization of smooth muscle. FEBS Letters 440 (1998) 183-187
13. 2 concentration in pulmonary hypertension associated with congenital heart disease. Circulation 90 (1994) 2952-2955
14. Gaine S.P., and Rubin L.J. Primary pulmonary hypertension. Lancet 352 (1998) 719-725
15. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A., Grimminger F., Kurzyna M., and Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine 353 (2005) 2148-2157
16. 2+ sensitization of smooth muscle. Proceedings of the National Academy of Sciences of the United States of America 93 (1996) 1340-1345
17. 2 receptor antagonists. Medicinal Research Reviews 11 (1991) 503-579
18. Huang Y., Tsang S.Y., Yao X., and Chen Z.Y. Biological properties of baicalein in cardiovascular system. Current drug targets. Cardiovascular & Haematological Disorders 5 (2005) 177-184
19. Kang D.G., Sohn E.J., Kwon E.K., Han J.H., Oh H., and Lee H.S. Effects of berberine on angiotensin-converting enzyme and NO/cGMP system in vessels. Vascular Pharmacology 39 (2002) 281-286
20. Kim Y.S., Jung E.A., Shin J.E., Chang J.C., Yang H.K., Kim N.J., Cho K.H., Bae H.S., Moon S.K., and Kim D.H. Daio-Orengedokuto inhibits HMG-CoA reductase and pancreatic lipase. Biological and Pharmaceutical Bulletin 25 (2002) 1442-1445
21. 2 inhibitor. Archives of Physiology and Biochemistry 111 (2003) 217-223
22. Lin W.C., and Tan T.W. The role of gastric muscle relaxation in cytoprotection induced by san-huang-xie-xin-tang in rats. Journal of Ethnopharmacology 44 (1994) 171-179
23. Lo Y.C., Lin Y.L., Yu K.L., Lai Y.H., Wu Y.C., Ann L.M., and Chen I.J. San-Huang-Xie-Xin-Tang attenuates inflammatory responses in lipopolysaccharide-exposed rat lungs. Journal of Ethnopharmacology 101 (2005) 68-74
24. Lo Y.C., Tsai P.L., Huang Y.B., Shen K.P., Tsai Y.H., Wu Y.C., Lai Y.H., and Chen I.J. San-Huang-Xie-Xin-Tang reduces lipopolysaccharides-induced hypotension and inflammatory mediators. Journal of Ethnopharmacology 96 (2005) 99-106
25. + channel opening and vasorelaxant properties. Journal of Pharmacology and Experimental Therapeutics 281 (1997) 253-260
26. Maruyama T., Ohsaki K., Shimoda S., Kaji Y., and Harada M. Thromboxane-dependent portopulmonary hypertension. American Journal of Medicine 118 (2005) 93-94
27. Mikhail G., Chester A.H., Gibbs J.S., Borland J.A., Banner N.R., and Yacoub M.H. Role of vasoactive mediators in primary and secondary pulmonary hypertension. American Journal of Cardiology 82 (1998) 254-255
28. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society 2 (2005) 20-22
29. Nagaoka T., Fagan K.A., Gebb S.A., Morris K.G., Suzuki T., Shimokawa H., McMurtry I.F., and Oka M. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 171 (2005) 494-499
30. Park E.K., Choo M.K., Yoon H.K., and Kim D.H. Antithrombotic and antiallergic activities of rhaponticin from Rhei Rhizoma are activated by human intestinal bacteria. Archives of Pharmacal Research 25 (2002) 528-533
31. Pulido E.J., Shames B.D., Fullerton D.A., Sheridan B.C., Selzman C.H., Gamboni-Robertson F., Bensard D.D., and McIntyre Jr. R.C. Differential inducible nitric oxide synthase expression in systemic and pulmonary vessels after endotoxin. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 278 (2000) R1232-R1239
32. Rabe K.F., Tenor H., Dent G., Schudt C., Nakashima M., and Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. American Journal of Physiology 266 (1994) L536-L543
33. Robertson T.P., Dipp M., Ward J.P., Aaronson P.I., and Evans A.M. Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat. British Journal of Pharmacology 131 (2000) 5-9
34. Roy R., and Couriel J.M. Secondary pulmonary hypertension. Paediatric Respiratory Reviews 7 (2006) 36-44
35. Runo J.R., and Loyd J.E. Primary pulmonary hypertension. Lancet 361 (2003) 1533-1544
36. Said S.I. Mediators and modulators of pulmonary arterial hypertension. American Journal of Physiology. Lung Cellular and Molecular Physiology 291 (2006) L547-L558
37. Sanae F., Komatsu Y., Chisaki K., Kido T., Ishige A., and Hayashi H. Effects of San'o-shashin-to and the constituent herbal medicines on theophylline-induced increase in arterial blood pressure of rats. Biological and Pharmaceutical Bulletin 24 (2001) 1137-1141
38. Schermuly R.T., Inholte C., Ghofrani H.A., Gall H., Weissmann N., Weidenbach A., Seeger W., and Grimminger F. Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. Respiratory Research 6 (2005) 76
39. Shih Y.T., Wu D.C., Liu C.M., Yang Y.C., Chen I.J., and Lo Y.C. San-Huang-Xie-Xin-Tang inhibits Helicobacter pylori-induced inflammation in human gastric epithelial AGS cells. Journal of Ethnopharmacology 112 (2007) 537-544
40. Tasaka S., Koh H., Yamada W., Shimizu M., Ogawa Y., Hasegawa N., Yamaguchi K., Ishii Y., Richer S.E., Doerschuk C.M., and Ishizaka A. Attenuation of endotoxin-induced acute lung injury by the Rho-associated kinase inhibitor, Y-27632. American Journal of Respiratory Cell and Molecular Biology 32 (2005) 504-510
41. Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., Tamakawa H., Yamagami K., Inui J., Maekawa M., and Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389 (1997) 990-994
42. Weimann J., Ullrich R., Hromi J., Fujino Y., Clark M.W., Bloch K.D., and Zapol W.M. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 92 (2000) 1702-1712
43. Wharton J., Strange J.W., Moller G.M., Growcott E.J., Ren X., Franklyn A.P., Phillips S.C., and Wilkins M.R. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. American Journal of Respiratory and Critical Care Medicine 172 (2005) 105-113
44. Zamora C.A., Baron D.A., and Heffner J.E. Thromboxane contributes to pulmonary hypertension in ischemia-reperfusion lung injury. Journal of Applied Physiology 74 (1993) 224-229